MedTrace Logo

Neuromelanin MRI: A Progression Marker in Early PD

NCT05631158 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 135

Last updated 2022-11-30

No results posted yet for this study

Summary

Prospective observational study to qualify NM-MRI as progression marker in early Parkinson's.

Conditions

  • Parkinson Disease
  • Progression, Disease

Interventions

DIAGNOSTIC_TEST

MRI

The clinical examination includes a short physical exam, a brief history of allergies, previous diseases and medications, and disease-related questionnaires. All the participants will undergo 4 serial MRI scans: one MRI scan at the baseline visit, 6, 12, 18 months follow-up visit, respectively to record the changes in the brain, which include the neuromelanin scan. For future proving the value of our study, we will also collect and store blood samples at the initial visit.

Sponsors & Collaborators

  • University of Nottingham

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2024-06-30
Completion
2024-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05631158 on ClinicalTrials.gov